title: Determination of sirolimus in rabbit arteries using liquid chromatography separation and tandem mass spectrometric detection.
abstract: Sirolimus, an effective immunosuppressive agent, is used for drug eluting stents. During stent development, an analytical method for the determination of sirolimus in tissue needs to be established. Normally, tissue samples are homogenized and then analyzed against the calibration standards prepared in a tissue homogenate. This approach provides insufficient control of the homogenization process. In this paper, tissue quality control samples were introduced for the optimization of the homogenization process during method development, but also allowance for the performance evaluation of the entire analytical process. In addition, a new approach using rabbit blood as a homogenization medium was developed to stabilize sirolimus in rabbit tissue homogenates. Calibration standards and quality controls were prepared by spiking different sirolimus working solutions into rabbit blood. Homogenization quality control samples were prepared by injecting other sirolimus working solutions into empty test tubes and pre-cut arteries within pre-defined masses. A high-throughput homogenization procedure was optimized based on the specific chemical properties of sirolimus. The linear dynamic range was between 49.9 pg/mL and 31.9 ng/mL to accommodate the expected artery homogenate concentrations. Additionally, quality controls in rabbit blood were also used in the extraction to support the calibration standards. The accuracy and precision of the quality controls in rabbit blood reflect the extraction performance and the accuracy and precision of the homogenization tissue quality controls reflect the overall performance of the method. The mean bias was between -4.5 and 0.2% for all levels of quality controls in the blood and between 4.8 and 14.9% for all levels of the homogenization tissue quality controls. The CVs of all concentration levels were < or =5.3% for the quality controls in blood and < or =9.2% for the homogenization tissue quality controls. The method was successfully applied to determine the concentration of sirolimus in the rabbit arteries.
authors.affiliation: Department of Drug Analysis, Abbott Laboratories, Abbott Park, IL 60064, USA. Jun.zhang@abbott.com
authors.forename: Jun
authors.initials: J
authors.lastname: Zhang
authors.forename: Ramona
authors.initials: R
authors.lastname: Rodila
authors.forename: Pamela
authors.initials: P
authors.lastname: Watson
authors.forename: Qin
authors.initials: Q
authors.lastname: Ji
authors.forename: Tawakol A
authors.initials: TA
authors.lastname: El-Shourbagy
mesh_terms: D000818:Animals; D001158:Arteries / Q000737:chemistry*; D005591:Chemical Fractionation / Q000379:methods; D002851:Chromatography, High Pressure Liquid; D023903:Coronary Restenosis / Q000517:prevention & control; D016903:Drug Monitoring / Q000379:methods; D004355:Drug Stability; D054855:Drug-Eluting Stents; D011786:Quality Control; D011817:Rabbits; D012015:Reference Standards; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D020123:Sirolimus / Q000031:analogs & derivatives / Q000032:analysis* / Q000097:blood / Q000138:chemical synthesis / Q000592:standards; D013048:Specimen Handling / Q000379:methods; D021241:Spectrometry, Mass, Electrospray Ionization; D053719:Tandem Mass Spectrometry; D014018:Tissue Distribution
chemical_list: C489443:zotarolimus; D020123:Sirolimus